Investigation Report on China Insulin Aspart Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||297279|
|出版日期||內容資訊||英文 30 Pages
|中國的速效胰島素市場分析 Investigation Report on China Insulin Aspart Market, 2010-2019|
|出版日期: 2015年07月24日||內容資訊: 英文 30 Pages||
2001年12月26日，Novo Nordisk開發了全球第一個胰島素類似物的速效胰島素(商品名「Novorapid」)，受到美國FDA(食品藥物管理局)的認證。並且2005年4月，第一個胰島素類似物「Novomix 30」(配合速效胰島素30％和速效胰島素魚精蛋白70％)也在中國上市。中國由於過去30年迅速的經濟發展使飲食習慣和生活方式急劇變化，肥胖相關疾病的患病人數持續增加。2013年終現在，中國的糖尿病患者數達到9800萬∼1億2000萬人。速效胰島素的市場規模，預計2005∼2013年之間擴大100倍以上，今後預期也將持續成長。
According to a report issued by WHO in 2014, the incidence of diabetes was estimated to be 9% among adults aged above 18 in the world. In 2012, diabetes reported an estimated 1.5 million cases of death, among which over 80% were in middle income and low income countries. And WHO made a prediction that diabetes will become the seventh leading cause of death by 2030. A nationwide diabetes survey carried out in 2010 in China showed that 11.6% of adults, that is 114 million people, suffered from diabetes and that the incidence of diabetes was 12.1% in men and 11% in women. And China has surpassed the US to become the country with the largest number of diabetes case.
Developed by Novo Nordisk, insulin aspart (under the trade name of Novolog) is an important drug for the treatment of diabetes. Compared with human insulin, insulin aspart, as a fast-acting insulin analog, starts working fast and reports higher peak of glucose-lowering action and lower risk of hypoglycemia. Ever since insulin aspart for injection was approved to enter China in 2012, it has been in the market for over a decade. Although the market is currently dominated by product of Novo Nordisk, some local enterprises are trying to make generic drugs. China Food and Drug Administration (CFDA) announced on its website on Jun.3, 2014 that Hisun's application to produce the APIs of insulin aspart and insulin aspart for injection through recombinant DNA technology has been accepted.
Insulin aspart develops fast after entering China. Its sales value reached CNY 336 million in 2013 and CNY 380 million in 2014 with a year-on-year increase of 13.10% while its sales volume reached 4.42 million in 2013 and 5.01 million in 2014, increasing 13.35% year on year. With economic development and lifestyle changes, the incidence of diabetes in China will keep going up, which fosters the huge demand for insulin aspart. Currently, the market is dominated by Novo Nordisk (Denmark) and Novo Nordisk (China), the former enjoying a larger market share of 100% with sales value reaching nearly CNY 380 million in 2014. As some local enterprises are trying to make generic drugs of insulin aspart, the monopoly of Novo Nordisk is expected to be broken by local products in the next few years.